RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat lymphoma in major trial
Disease control OngoingThis study tests a personalized cell therapy (axicabtagene ciloleucel) against standard treatments for people with follicular lymphoma that has returned or not responded to prior therapy. About 231 participants will receive either the cell therapy or usual care. The main goal is …
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New hope for hard-to-treat lymphoma: drug combo aims to keep cancer at bay
Disease control OngoingThis study is for people with follicular lymphoma, a type of blood cancer, that has returned or no longer responds to treatment. It tests whether adding the drug tazemetostat to a standard two-drug combination can help patients live longer without their cancer getting worse. Abou…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 17, 2026 02:05 UTC